Αποτελέσματα Αναζήτησης
3 Σεπ 2024 · For patients with alcohol use disorder who are taking opioid agonists (eg, oxycodone) for a clinically indicated use (eg, pain management), naltrexone must be avoided.
- Contributor Disclosures
Stephen R Holt, MD, MS, FACP Disclosure: No relevant...
- Christensen C. Management of Chemical Dependence in Pregnancy. Clin Obstet Gynecol 2008; 51:445
Although most interventions for college students are...
- Skinner Md, Lahmek P, Pham H, Aubin Hj. Disulfiram Efficacy in The Treatment of Alcohol Dependence: a Meta-Analysis. PLoS One 2014; 9:E87366
Efficacy of long-acting, injectable versus oral naltrexone...
- Anton Rf, Latham P, Voronin K, Et Al. Efficacy of Gabapentin for The Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: a Randomized Clinical Trial. JAMA Intern Med 2020; 180:728
UpToDate, electronic clinical resource tool for physicians...
- Kranzler Hr, Feinn R, Morris P, Hartwell Ee. a Meta-Analysis of The Efficacy of Gabapentin for Treating Alcohol Use Disorder. Addiction 2019; 114:1547
One group received naltrexone 12.5 mg once daily for 3 days,...
- Hartung Dm, McCarty D, Fu R, Et Al. Extended-release Naltrexone for Alcohol and Opioid Dependence: a Meta-Analysis of Healthcare Utilization Studies. J Subst Abuse Treat 2014; 47:113
Extended-release naltrexone for alcohol and opioid...
- De Bejczy A, Löf E, Walther L, Et Al. Varenicline for Treatment of Alcohol Dependence: a Randomized, Placebo-Controlled Trial. Alcohol Clin Exp Res 2015; 39:2189
RESULTS Fourteen double-blind RCTs (1522 patients) were...
- GBD 2016 Alcohol and Drug Use Collaborators. The Global Burden of Disease Attributable to Alcohol and Drug Use in 195 Countries and Territories, 1990-2016: a Systematic Analysis for The Global Burden of Disease Study 2016. Lancet Psychiatry 2018; 5:987
1 PubMed | TI The global burden of disease attributable to...
- Contributor Disclosures
1 Δεκ 2022 · As an opioid antagonist that alters dopamine release following alcohol use, naltrexone is thought to help with craving and alcohol-related euphoria. One limitation of the existing evidence for medications is that most studies on problematic alcohol use and medications for AUD focus on severe AUD and ignore binge-drinking populations.
14 Αυγ 2008 · The ideal patient for naltrexone therapy would be a person who has moderate-to-severe alcohol dependence — for example, a person who drinks on more than 50% of days, consumes more than...
13 Δεκ 2001 · Naltrexone was incorporated into the treatment of alcoholism on the premise that stimulation of the μ opioid receptor contributed to the rewarding effects of alcohol. 5–7 Data from clinical...
5 Σεπ 2012 · Oral naltrexone is relatively safe and has a moderate to good clinical efficacy in the management of persons with alcohol dependence [5, 6]. Meta-analysis studies have concluded that the use of naltrexone is most appropriate where controlled drinking is the desired outcome [7, 8].
Naltrexone reduces both the rewarding effects of alcohol and craving for it. Brief History of Development. Naltrexone was first synthesized in 1963 by Endo Laboratories, which was acquired by DuPont in 1969.
20 Μαΐ 2020 · There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, naltrexone (oral and long-acting injectable), and acamprosate.
